terameprocol

inhibits HIV Tat-regulated transactivation; structure in first source

Also Known As:

4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-dimethoxybenzene; FW 358.2; FW-358.2; TMNDGA; tetra-O-methyl-NDGA; tetra-O-methylnordihydroguaiaretic acid; tetramethoxynordihydroguaiaretic acid

Networked: 15 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        Catechols: 121
        Masoprocol: 223
        terameprocol: 15
        Benzyl Compounds: 2
        Lignans: 1113
        Masoprocol: 223
        terameprocol: 15

Experts

1.	Ahluwalia, Manmeet S: 1 article (02/2022)
2.	Anders, Nicole M: 1 article (02/2022)
3.	Hemingway, Avelina: 1 article (02/2022)
4.	Romo, Carlos G: 1 article (02/2022)
5.	Rudek, Michelle A: 1 article (02/2022)
6.	Chao, Angel: 1 article (11/2018)
7.	Chen, Shu-Jen: 1 article (11/2018)
8.	Lai, Chyong-Huey: 1 article (11/2018)
9.	Lee, Li-Yu: 1 article (11/2018)
10.	Lee, Yun-Shien: 1 article (11/2018)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2007 - "This trial was designed to define the maximum tolerated dose (MTD), dose-limiting toxicity and determine the pharmacokinetic profiles of intravaginal terameprocol in women with HPV-linked cervical squamous intraepithelial neoplasia. " 08/15/2009 - "The analogs were evaluated for cytotoxicity in four cancer cell lines and compared to NDGA and tetra-O-methyl-NDGA (M4N) (1a). " 03/01/2008 - "In a phase I clinical trial in patients (25 evaluable) with solid tumors administered intravenous terameprocol, 8 patients exhibited stable disease and 17 had progressive disease; the drug was generally well tolerated. " 09/01/2007 - "The terameprocol CPE formulation showed no overt toxicities in tumor-bearing mice. " 09/01/2007 - "Terameprocol is in clinical development as a site-specific transcription inhibitor in solid refractory tumors. "
2.	Glioma (Gliomas) 04/01/2012 - "Phase I study of terameprocol in patients with recurrent high-grade glioma." 02/05/2022 - "The method was applied to the measurement of total plasma concentrations of terameprocol in a patient with a high-grade glioma receiving a 300 mg oral dose." 02/05/2022 - "The global transcription inhibitor terameprocol is being evaluated clinically as an oral formulation to treat high-grade glioma. " 04/01/2012 - "The long-term stability noted in some patients and the lack of associated myelosuppression suggest that terameprocol could be safely combined with radiation and temozolomide in newly diagnosed high-grade gliomas." 03/01/2008 - "At the time of publication, terameprocol was in phase I or I/II clinical development for the treatment of glioma, treatment-refractory solid tumors and cervical dysplasia; a phase I clinical trial was also planned in patients with hematological cancers. "
3.	Uterine Cervical Dysplasia 12/01/2007 - "Terameprocol in 1% and 2% vaginal ointment use in Phase I/II trials with women with HPV-linked cervical intraepithelial neoplasia has an excellent safety profile, no SAEs reported and mild, self-limiting treatment-related AEs. " 03/01/2008 - "A good safety and efficacy profile has also been observed with the intratumoral and intravaginal administration of terameprocol in patients with head and neck or squamous cell carcinoma and in patients with cervical dysplasia, respectively. " 03/01/2008 - "At the time of publication, terameprocol was in phase I or I/II clinical development for the treatment of glioma, treatment-refractory solid tumors and cervical dysplasia; a phase I clinical trial was also planned in patients with hematological cancers. "
4.	Lung Neoplasms (Lung Cancer) 01/01/2011 - "Further study is warranted to assess the potential of terameprocol as an agent that may enhance the therapeutic ratio of radiotherapy in lung cancer." 01/01/2011 - "This study examined the effects of terameprocol administration on survivin transcription and expression in HCC2429 and H460 lung cancer cells. "
5.	Leukemia 04/01/2015 - "Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias." 04/01/2015 - "Terameprocol can be safely administered to advanced leukemia patients, sufficient drug exposure was obtained and clinical activity and biomarker modulation were observed."

Related Drugs and Biologics

1.	terameprocol
2.	Thymidine Monophosphate (TMP)
3.	Powders
4.	Ointments (Pastes)
5.	Dimethyl Sulfoxide (DMSO)
6.	Survivin
7.	2-Hydroxypropyl-beta-cyclodextrin
8.	polyethylene glycol 300
9.	Lignans
10.	Masoprocol (Actinex)

Related Therapies and Procedures

1.	Radiotherapy
2.	Intravaginal Administration